AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $437K and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$437K netNet selling
- CongressSTOCK Act, last 180 days
- -$15K to -$50K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 7 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 26- Open
- $61.75
- 52-wk high
- $68.64
- High
- $62.91
- 52-wk low
- $41.13
- Low
- $61.40
- Prev close
- $61.50
- Mkt cap
- $128.41B
- P/E
- 13.8x
- Volume
- 10.03M
- Fwd P/E
- 9.4x
- Beta
- 0.23
- Div yield
- 4.08%
- P/S
- 2.6x
- P/B
- 5.6x
- Profit margin
- +18.9%
- Op margin
- +34.4%
- ROE
- +46.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BMY filings
Are insiders buying or selling Bristol-Myers Squibb Company (BMY) stock?
Net selling: insiders sold $437K and bought $0 of BMY stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. The largest was Massacesi, Cristian (EVP,Chief Med Offr,Head of Dev), who sold $403K. The latest filing was on Sep 10, 2026.
Which members of Congress have traded BMY recently?
Rep. Mike Kelly (R) sold $15K to $50K on May 7, 2026, disclosed 35 days later. In total, 1 member disclosed 1 BMY trade with trade dates in the last 180 days, filed a median 35 days after trading.
How current is this BMY smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (3)
- MI
Millennium
$353.6M
trimmed
- P7
Point72
$32.2M
sold
- SU
Susquehanna
$25.7M
trimmed
What insiders are doing
What Congress is doing
Sells (1)
How top traders are positioned
No tracked top-trader positions in BMY right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 28.3% above what analysts expected.
Earnings per share
$1.59 expected
Reports Oct 29, 2026, in 32 days
Estimates as of Sep 26, 2026
EPS expected
$1.59 to $1.92
Revenue expected
19 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Cost of what it sold | $3.44B | $4.10B | $3.42B | $3.73B |
| Gross profit | $8.79B | $8.41B | $8.07B | $9.25B |
| What it spent | ||||
| Research and development | $2.53B | $2.59B | $2.65B | $2.96B |
| Sales and admin | $1.79B | $2.18B | $1.62B | $1.83B |
| Other operating costs | $831.0M | $826.0M | $437.0M | $376.0M |
| Total operating expenses | $5.15B | $5.59B | $4.70B | $5.16B |
| What was left | ||||
| Operating profit | $3.64B | $2.81B | $3.37B | $4.09B |
| Interest on debt | $480.0M | $432.0M | $411.0M | $407.0M |
| Profit before tax | $3.11B | $1.47B | $3.24B | $4.09B |
| Tax | $919.0M | $384.0M | $561.0M | $770.0M |
| Net profit | $2.20B | $1.09B | $2.68B | $3.32B |
| EBITDA | $4.61B | $2.88B | $4.25B | $4.94B |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
NJ pharma giant cuts 265 more jobs — bringing 2026 layoffs to 718, so far
Leans bearishSep 23Goldman Sachs reiterates Bristol-Myers Squibb stock Neutral rating
NeutralSep 23Top 10: Chief Digital Officers in Healthcare
Leans bullishSep 23Is Pfizer (PFE) Getting Too Pricey After Its 24% Rise?
NeutralSep 23Bristol Myers cuts another 265 jobs tied to New Jersey headquarters
Leans bearishSep 22State Street Corp Has $6.09 Billion Stock Position in Bristol Myers Squibb Company $BMY
BullishSep 22Travere Therapeutics Names Bradley Campbell CEO
NeutralSep 22Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
NeutralSep 22